James Barder, Futura’s chief executive, tells Proactive the agreement means deals are in place in all the major erectile dysfunction markets in the world with the exception of the US and Canada.
Here, Futura is waiting for the completion of the current clinical study, which is on track for results in early September.
Barder adds, importantly, Cooper carried out its own home use test before signing, which is the first time MED3000 had been tested outside the clinic in real-world use.